Table 3. Details of cytogenetic... | American Society of Hematology

Table 3.

Details of cytogenetic responses

Patient	Ph⁺ % on conventional imatinib mesylate, lowest/preincrease	Lowest Ph⁺ % after dose increase	Improved cytogenetic response, type and duration^3-150/mo
1	50/55	0	CR/6+
2	5/70	0	CR/6+
3	40/100	0	CR/5+
4	20/40	0	CR/2+
5	0/55	0	CR/1+
6	100/100^3-151	10	PR/17
7	0/55	10	PR/15
8	50/85	15	PR/1+
9	5/45	20	PR/3+
10	90/90	25	PR/1+
11	90/90	40	PR/6+
12	66/100	40	Minor/1+
13	75/75	42	PR/5+
14	100/100	45	Minor/11
15	100/100	45	Minor/1+
16	100/100^3-151	50	Minor/1+
17	0/95	70	Minor/2
18	45/100	3 (FISH)	CR/11+
19	100/100	27 (FISH)	PR/1+
20	85/100	34 (FISH)	Minor/1+
21	100/100	55 (FISH)	Minor/11+

Patient	Ph⁺ % on conventional imatinib mesylate, lowest/preincrease	Lowest Ph⁺ % after dose increase	Improved cytogenetic response, type and duration^3-150/mo
1	50/55	0	CR/6+
2	5/70	0	CR/6+
3	40/100	0	CR/5+
4	20/40	0	CR/2+
5	0/55	0	CR/1+
6	100/100^3-151	10	PR/17
7	0/55	10	PR/15
8	50/85	15	PR/1+
9	5/45	20	PR/3+
10	90/90	25	PR/1+
11	90/90	40	PR/6+
12	66/100	40	Minor/1+
13	75/75	42	PR/5+
14	100/100	45	Minor/11
15	100/100	45	Minor/1+
16	100/100^3-151	50	Minor/1+
17	0/95	70	Minor/2
18	45/100	3 (FISH)	CR/11+
19	100/100	27 (FISH)	PR/1+
20	85/100	34 (FISH)	Minor/1+
21	100/100	55 (FISH)	Minor/11+

CG indicates cytogenetic response; CR, complete response; PR, partial response; and FISH; fluorescent in situ hybridization.

From date improvement first documented.

Hematologic resistance.